Videos

Thomas Lodise, PharmD, PhD, discusses why "time to clinical response" is a valuable metric to use in clinical studies.

Minh-Hong Nguyen, MD, explains why it's so important to continue developing new antifungal drugs.

Steven Tong, PhD, discusses the next steps for research on combination therapy for MRSA bacteremia.

Vanessa Stevens, PhD, discusses her research on fluoroquinolone and cephalosporin prescribing and rates of Clostridium difficile infections at VA health care facilities.

Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.

Elizabeth Hirsch, PharmD, and Mélanie Mahoney, PharmD candidate, discuss their poster on Escherichia coli ST131 in Boston vs Minneapolis at ECCMID 2019.

Marin Kollef, MD, discusses recently approved agents targeting antibiotic resistant gram-negative bacteria and what to expect in the next 5 years.

Tristan Ferry, MD, PhD, discusses why there is a need to develop alternatives to treat chronic bone and joint infections.

Laura Shallcross, PhD, discusses how clinicians have “a low threshold” for initiating antibiotics in the emergency department for patients with symptoms similar to a UTI.

Leslie Tari, PhD, discusses Cidara Therapeutics' Cloudbreak antiviral initiatives.

Melanie Nicol, PharmD, PhD, explores how DMPA hormonal contraception affects women's HIV risk.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Paul Sax, MD, names the DISCOVER study as one of the highlights of CROI 2019.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

Kavita Misra, PhD, MPH, explains how health care providers can help prevent PrEP resistance from growing by increasing screening for acute HIV infection.

Julia Marcus, PhD, MPH, discusses the barriers of PrEP use and how current prescribing guidelines are used in clinical practice.

Paul Sax, MD, details his research on integrase inhibitor-based regimens and weight gain.

Brad Hare, MD, explains how the findings of the DISCOVER study indicate that PrEP is no longer a one-size-fits-all situation.

Bluma Brenner, PhD, confesses that HIV "terrifies the hell" out of her, as it continues to build resistance against existing therapy regimens.

Laura Waters, MD, FRCP, an author on the Nature article on the reported HIV remission of the London Patient, explains why it is too soon to label the remission as a cure.

Paul Sax, MD, shares his take on news of the second person ever achieving long-term HIV remission.

Ava Avalos, MD, discusses the "encouraging" 12-month outcomes from the Botswana Beat Cohort study, which employs a dolutegravir-based regimen.